129 related articles for article (PubMed ID: 9013289)
1. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
Fitzgerald RL; Herold DA
J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the diagnostic performance of the Boehringer Mannheim CEDIA LSD assay.
Verstraete AG; Steyaert S
J Anal Toxicol; 1998; 22(7):601-4. PubMed ID: 9847012
[TBL] [Abstract][Full Text] [Related]
3. Comparison of EMIT II, CEDIA, and DPC RIA assays for the detection of lysergic acid diethylamide in forensic urine samples.
Wiegand RF; Klette KL; Stout PR; Gehlhausen JM
J Anal Toxicol; 2002 Oct; 26(7):519-23. PubMed ID: 12423010
[TBL] [Abstract][Full Text] [Related]
4. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
Darragh A; Snyder ML; Ptolemy AS; Melanson S
Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
Fraser AD; Meatherall R
J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
[TBL] [Abstract][Full Text] [Related]
6. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
Mina A
J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
[TBL] [Abstract][Full Text] [Related]
7. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
Fraser AD; Howell P
J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
[TBL] [Abstract][Full Text] [Related]
8. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
Dixon RB; Floyd D; Dasgupta A
Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
[TBL] [Abstract][Full Text] [Related]
9. Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography-mass spectrometry.
Nishikawa T; Ohtani H; Herold DA; Fitzgerald RL
Am J Clin Pathol; 1997 Mar; 107(3):345-52. PubMed ID: 9052386
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the CEDIA and EMIT II immunoassays for the determination of benzodiazepines.
Way BA; Walton KG; Koenig JW; Eveland BJ; Scott MG
Clin Chim Acta; 1998 Mar; 271(1):1-9. PubMed ID: 9564553
[TBL] [Abstract][Full Text] [Related]
11. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay.
Fraser AD; Meatherall R
Ther Drug Monit; 1998 Jun; 20(3):331-4. PubMed ID: 9631932
[TBL] [Abstract][Full Text] [Related]
12. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
Schwettmann L; Külpmann WR; Vidal C
Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
[TBL] [Abstract][Full Text] [Related]
13. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
Pettersson Bergstrand M; Helander A; Hansson T; Beck O
Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
[TBL] [Abstract][Full Text] [Related]
14. Optimization of cloned enzyme donor immunoassay cut-offs for drugs of abuse in whole blood of drivers involved in road accidents.
Pelletti G; Garagnani M; Rossi F; Roffi R; Barone R; Pelotti S
Forensic Sci Int; 2019 Jan; 294():27-33. PubMed ID: 30447484
[TBL] [Abstract][Full Text] [Related]
15. Comparison of drugs of abuse detection in meconium by EMIT II and ELISA.
Marin SJ; Keith L; Merrell M; McMillin GA
J Anal Toxicol; 2009 Apr; 33(3):148-54. PubMed ID: 19371463
[TBL] [Abstract][Full Text] [Related]
16. Improved screening for benzodiazepine metabolites in urine using the Triage Panel for Drugs of Abuse.
Koch TR; Raglin RL; Kirk S; Bruni JF
J Anal Toxicol; 1994; 18(3):168-72. PubMed ID: 7914948
[TBL] [Abstract][Full Text] [Related]
17. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening.
Armbruster DA; Hubster EC; Kaufman MS; Ramon MK
Clin Chem; 1995 Jan; 41(1):92-8. PubMed ID: 7813088
[TBL] [Abstract][Full Text] [Related]
18. New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics.
Schwenzer KS; Pearlman R; Tsilimidos M; Salamone SJ; Cannon RC; Wong SH; Gock SB; Jentzen JJ
J Anal Toxicol; 2000; 24(8):726-32. PubMed ID: 11110029
[TBL] [Abstract][Full Text] [Related]
19. CEDIA for screening drugs of abuse in urine and the effect of adulterants.
Wu AH; Forte E; Casella G; Sun K; Hemphill G; Foery R; Schanzenbach H
J Forensic Sci; 1995 Jul; 40(4):614-8. PubMed ID: 7595298
[TBL] [Abstract][Full Text] [Related]
20. LSD screening in urine performed by CEDIA® LSD assay: positive interference with sertraline.
Citterio-Quentin A; Seidel E; Ramuz L; Parant F; Moulsma M
J Anal Toxicol; 2012 May; 36(4):289-90. PubMed ID: 22511703
[No Abstract] [Full Text] [Related]
[Next] [New Search]
